Argenica Therapeutics reports wider loss amid increased R&D spending

Argenica Therapeutics Limited reported a net loss after income tax of A$7,170,347 for the year ended June 30, 2025, a 31% increase from A$5,479,488 in the previous year. Total revenue from ordinary activities rose 34% to A$3,726,499. This revenue included an A$2,757,459 R&D tax incentive rebate and A$512,751 in interest income.

The wider loss was primarily driven by increased operating expenses, with research and development costs rising to A$8,132,295 from A$6,016,753 in 2024. Net operating cash outflows for the period were A$5,704,397. The company's net asset position decreased to A$7,237,271 from A$13,950,835, with cash and cash equivalents at A$10,555,160.

Post-reporting period, Argenica secured A$1,500,000 in non-dilutive funding, with an initial A$1,000,000 grant executed on July 1, 2025. Additionally, 11,522 ordinary shares were issued on July 7, 2025, following the cashless exercise of 125,000 options.